All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Targeting Menin: A New Frontier in Treating Refractory Leukemias

February 28th 2025

Incorporation of menin inhibitors is central to improving the outcome of difficult-to-treat leukemias.

Beyond Serum Tryptase: Exploring Additional Testing Approaches for Indolent Systemic Mastocytosis

February 28th 2025

Tracy I. George, MD, discusses testing considerations in indolent systemic mastocytosis, including the role of serum tryptase and KIT D816V testing.

Efficacy and Safety of Nadofaragene Firadenovec Hold Up in NMIBC Real-World Study

February 27th 2025

The intravesical therapy nadofaragene firadenovec yielded a 79% 3-month CR rate in patients with CIS with or without papillary disease in a real-world study.

Clinical Trials, Randomized Data Are Key to Further Refine Treatment Selection in Advanced Non–Clear Cell RCC

February 27th 2025

Charles B. Nguyen, MD, provides insight into current challenges faced in the non–clear cell RCC landscape beyond the NCCN’s recent guideline updates.

The Rapid Evolution of Multiple Myeloma Treatment in Recent Years

February 27th 2025

Multiple myeloma experts offer their perspectives on the evolution of the treatment landscape over the past 10 years and look towards the future of care.

Text Message Tool Addresses "Time Toxicity" for Patients With Cancer

February 27th 2025

In pilot study, patients saved over an hour of time at every treatment visit.

Ipilimumab Injection Plus Sintilimab Receives Priority Review in China for MSI-H/dMMR Colon Cancer

February 27th 2025

China’s NMPA has granted priority review to an NDA for neoadjuvant ipilimumab injection plus sintilimab in MSI-H or dMMR colon cancer.

Zamto-Cel Represents Potential New CAR T Approach in R/R DLBCL

February 27th 2025

Nirav N. Shah, MD, discusses findings from the phase 2 DALY II USA of zamto-cel in relapsed/refractory DLBCL.

FDA Grants Fast Track Designation to PYX-201 for Recurrent/Metastatic HNSCC

February 27th 2025

PYX-201 has received fast track designation from the FDA for patients with recurrent or metastatic HNSCC following progression with chemoimmunotherapy.

Drawing Professional Inspiration From Personal Experience

February 27th 2025

Bradley Muller, MD, discusses how his experience as a patient with cancer led to him working to improve outcomes for the next generation of patients.

Etentamig With Step-Up Dosing Shows Preliminary Efficacy, Safety in R/R Myeloma

February 27th 2025

Step-up dosing with etentamig produced responses and low rates of CRS in relapsed/refractory multiple myeloma.

Escalating Lymphodepletion ± Rituximab Before CD19-Directed CAR T-Cell Therapy is Safe in R/R DLBCL

February 27th 2025

Escalating doses of lymphodepleting chemotherapy with or without rituximab prior to CAR T-cell therapy was safe in relapsed/refractory DLBCL.

Divesiran Is Tolerable and Shows Positive Early Signals in Polycythemia Vera

February 26th 2025

The siRNA divesiran was well-tolerated and reduced the number of phlebotomies that were required in patients with polycythemia vera.

Tips for Tomorrow: What 4 Experts Wish They Knew Earlier About ADCs

February 26th 2025

Clinicians with years of ADC therapy experience provide insights on the drug class and what is most important to keep in mind when treating patients.

Multidisciplinary Collaboration Is Vital for Timely, Definitive Diagnosis of Indolent Systemic Mastocytosis

February 26th 2025

Andrew Kuykendall, MD, discusses the importance of a nuanced, multidisciplinary approach to expedite the diagnosis of indolent systemic mastocytosis.

Fox Chase Cancer Center and Temple Health Welcome Alyssa R. Goldbach, DO

February 26th 2025

Alyssa R. Goldbach, DO, is joining Fox Chase Cancer Center as an assistant professor for Breast Imaging in the Department of Diagnostic Imaging.

First-Line Camizestrant Plus CDK4/6 Inhibition Boosts PFS in ESR1+, HR+/HER2-Negative Advanced Breast Cancer

February 26th 2025

Camizestrant plus a CDK4/6 inhibitor was safe and effective in frontline ESR1-mutated HR-positive/HER2-negative advanced breast cancer.

FDA Accepts Resubmission of BLA for Odronextamab in R/R Follicular Lymphoma

February 26th 2025

The resubmission of a BLA for odronextamab was accepted by the FDA for the treatment of patients with relapsed/refractory follicular lymphoma.

Innovation in the Classroom

February 26th 2025

Faculty at Hackensack Meridian School of Medicine developed a novel curriculum to improve medical training through practical, clinic-focused learning.

Orca-Q Delivers Early Evidence of GVHD Risk Mitigation in Hematologic Malignancies

February 26th 2025

Amandeep Salhotra, MD, discusses data that have demonstrated the anti-GVHD activity of post-transplant Orca-Q in patients with hematologic malignancies.